Rosenzweig Michael - Dept Hematol & Hematopoiet Transplantat, City Hope Comprehens Canc Ctr

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 77 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Phase 1 Study of Bortezomib, Fludarabine, and Melphalan, With or Without Total Marrow Irradiation, as Allogeneic Hematopoietic Stem Cell Transplant Conditioning for High-risk or Relapsed/Refractory Multiple Myeloma

Colton Ladbury,James Sanchez,Arnab Chowdhury,Joycelynne Palmer,An Liu,Anthony Stein,Myo Htut,Leonardo Farol,Ji-Lian Cai,George Somlo,Michael Rosenzweig,Jeffrey C Wong,

American journal of clinical oncologyno. 7 (2024): 325-332

Cited0Views0WOSBibtex

Diagnostic utility of left atrial and right ventricular strain analyses in patients with AL amyloidosis

Faizi Jamal, Stephanie Wu, June-Wha Rhee, James Sanchez, Arnab Chowdhury, Carlos Gomez, Aleksi Lukuridze, Caitlyn Estrada, Meagan Echevarria, Lanie Lindenfeld,Saro Armenian,Michael Rosenzweig

crossref（2024）

Cited0Views0Bibtex

Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant

June-Wha Rhee,Raju Pillai,Tianhui He,Alysia Bosworth,Sitong Chen,Liezl Atencio,Artem Oganesyan,Kelly Peng,Tati Guzman,Kara Lukas,Brianna Sigala,Aleksi Iukuridze,

JAMA CARDIOLOGYno. 1 (2024): 16-24

Cited0Views0Bibtex

Single-Cell Mass Cytometry Analysis Reveals a Prominent Immune Suppressive Signature in AL Amyloidosis PA48 (#525)

Theophilus Tandoh,Mahmoud Singer,Arnab Chowdhury,Alex Pozhitkov, Preeti Sharma,Milad Moloudizargari,James Sanchez,Joycelynne Palmer, Scott R, Steven T,Michael Rosenzweig

crossref（2024）

Cited0Views0Bibtex

Trial in Progress: A Phase 1/1a Study of Venetoclax, Ixazomib and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis

Michael Rosenzweig,Vaishali Sanchorawala,James Sanchez,Arnab Chowdhury, Amandeep Godara, Miguel Villalona-Calero, Steven Gore, Craig Hofmeister, Carol Ann, John Wright, Rabih Said

crossref（2024）

Cited0Views0Bibtex

Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study

Corinna La Rosa,Flavia Chiuppesi,Yoonsuh Park,Qiao Zhou,Dongyun Yang,Ketevan Gendzekhadze,Minh Ly,Jing Li,Teodora Kaltcheva,Sandra Ortega Francisco,Miguel-Angel Gutierrez,Haris Ali,

Front Immunol（2023）

Cited1Views0WOSBibtex

A phase 2 trial of leflunomide, pomalidomide, and dexamethasone for relapsed/refractory multiple myeloma

Michael Rosenzweig,James Sanchez,Arnab Chowdhury,Nitya Nathwani,Murali Janakiram,Myo Htut,Firoozeh Sahebi, Tricia Walker,Flavia Pichiorri,Joycelynne Palmer,Amrita Krishnan,Jonathan Keats,

Clinical Lymphoma Myeloma and Leukemia (2023): S153-S153

Cited0Views0Bibtex

Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in a Diverse Patient Population with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius

Michael Rosenzweig,Yvonne Efebera,Efstathios Kastritis,Brandon Blue,Faizi Jamal,Monique C. Minnema, Christopher Pericone,Sandra Vasey, Yuping Chen, Sonja Kotoulek, Bart Vandael, Joana Duran,

BLOOD (2023): 4785

Cited0Views0Bibtex

Impact of Health Insurance and Access to Autologous Stem Cell Transplantation (ASCT) on Racial Inequity in Overall Survival (OS) Among Patients with Multiple Myeloma (MM)

F. Lennie Wong,Scott R. Goldsmith,Kimlin Ashing, Amrita Krishnan,Michael Rosenzweig,Saro Armenian

BLOOD（2023）

Cited0Views0Bibtex

Herpesvirus Entry Mediator As a Novel Therapeutic Target in Multiple Myeloma

Milad Moloudizargari,Ada Alice Dona,Miso Park,Theophilus Tandoh,Mariam Murtadha,Enrico Caserta,Alexander Pozhitkov,Yinghui Zhu,Ottavio Napolitano,James Sanchez,Lokesh Nigam, Amanda Duplan,

BLOOD（2023）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn